99 related articles for article (PubMed ID: 16681640)
1. Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status.
Yeh HS; Chen H; Manyak SJ; Swift RA; Campbell RA; Wang C; Li M; Lee HJ; Waterman G; Gordon MS; Ma J; Bonavida B; Berenson JR
Br J Haematol; 2006 Jun; 133(5):526-9. PubMed ID: 16681640
[TBL] [Abstract][Full Text] [Related]
2. Potential usefulness of serum p53 for laboratory management of plasma cell dyscrasias.
Greco C; Alvino S; Del Monte G; Venturo I; Lopez M
J Exp Clin Cancer Res; 2003 Dec; 22(4):607-12. PubMed ID: 15053303
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma.
Pappa C; Miyakis S; Tsirakis G; Sfiridaki A; Alegakis A; Kafousi M; Stathopoulos EN; Alexandrakis MG
Cytokine; 2007 Feb; 37(2):171-5. PubMed ID: 17446083
[TBL] [Abstract][Full Text] [Related]
4. [The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Bacovský J; Minarík J; Heinzová V; Langová K
Cas Lek Cesk; 2009; 148(7):315-22. PubMed ID: 19642297
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Minarík J; Zemanová M; Bacovský J; Heincová V;
Vnitr Lek; 2006 Mar; 52(3):232-40. PubMed ID: 16722154
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
[TBL] [Abstract][Full Text] [Related]
7. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib.
Anargyrou K; Terpos E; Vassilakopoulos TP; Pouli A; Sachanas S; Tzenou T; Masouridis S; Christoulas D; Angelopoulou MK; Dimitriadou EM; Kalpadakis C; Tsionos K; Panayiotidis P; Dimopoulos MA; Pangalis GA; Kyrtsonis MC;
Haematologica; 2008 Mar; 93(3):451-4. PubMed ID: 18287135
[TBL] [Abstract][Full Text] [Related]
8. The significance of soluble CD138 in diagnosis of monoclonal gammopathies.
Maisnar V; Tousková M; Tichý M; Krejsek J; Chrobák L; Voglová J; Malý J
Neoplasma; 2006; 53(1):26-9. PubMed ID: 16416009
[TBL] [Abstract][Full Text] [Related]
9. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the mitogenic, angiogenic and tumorigenic activities of pleiotrophin by a synthetic peptide corresponding to its C-thrombospondin repeat-I domain.
Hamma-Kourbali Y; Bernard-Pierrot I; Heroult M; Dalle S; Caruelle D; Milhiet PE; Fernig DG; Delbé J; Courty J
J Cell Physiol; 2008 Jan; 214(1):250-9. PubMed ID: 17607711
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment.
Heider U; Kaiser M; Mieth M; Lamottke B; Rademacher J; Jakob C; Braendle E; Stover D; Sezer O
Eur J Haematol; 2009 Jan; 82(1):31-8. PubMed ID: 19067746
[TBL] [Abstract][Full Text] [Related]
12. Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth.
Chen H; Gordon MS; Campbell RA; Li M; Wang CS; Lee HJ; Sanchez E; Manyak SJ; Gui D; Shalitin D; Said J; Chang Y; Deuel TF; Baritaki S; Bonavida B; Berenson JR
Blood; 2007 Jul; 110(1):287-95. PubMed ID: 17369488
[TBL] [Abstract][Full Text] [Related]
13. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
14. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden.
Feyler S; von Lilienfeld-Toal M; Jarmin S; Marles L; Rawstron A; Ashcroft AJ; Owen RG; Selby PJ; Cook G
Br J Haematol; 2009 Mar; 144(5):686-95. PubMed ID: 19133978
[TBL] [Abstract][Full Text] [Related]
15. [Contribution to the evaluation of the relationship between angiogenic cytokines, selected biological parameters and prognostic factors in multiple myeloma].
Scudla V; Pika T; Budíková M; Ordeltová M; Minarík J; Zemanová M; Bacovský J; Srovnalík K;
Cas Lek Cesk; 2006; 145(12):929-35. PubMed ID: 17323615
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
17. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.
Kaiser M; Mieth M; Liebisch P; Oberländer R; Rademacher J; Jakob C; Kleeberg L; Fleissner C; Braendle E; Peters M; Stover D; Sezer O; Heider U
Eur J Haematol; 2008 Jun; 80(6):490-4. PubMed ID: 18331598
[TBL] [Abstract][Full Text] [Related]
18. Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response.
Katodritou E; Ganz T; Terpos E; Verrou E; Olbina G; Gastari V; Hadjiaggelidou C; Varthaliti M; Georgiadou S; Westerman M; Zervas K
Am J Hematol; 2009 Aug; 84(8):524-6. PubMed ID: 19536845
[No Abstract] [Full Text] [Related]
19. Pleiotrophin as a potential biomarker in breast cancer patients.
Ma J; Kong Y; Nan H; Qu S; Fu X; Jiang L; Wang W; Guo H; Zhao S; He J; Nan K
Clin Chim Acta; 2017 Mar; 466():6-12. PubMed ID: 28041942
[TBL] [Abstract][Full Text] [Related]
20. Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies.
Quartarone E; Alonci A; Allegra A; Bellomo G; Calabrò L; D'Angelo A; Del Fabro V; Grasso A; Cincotta M; Musolino C
Eur J Haematol; 2006 Dec; 77(6):480-5. PubMed ID: 16978237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
